Explore News
-
Why GSK is Acquiring Nuvalent for $10.6 Billion
GSK’s acquisition of Nuvalent marks a significant move in the pharma industry
-
Why GSK’s New Cancer Drug is Causing a Stir
New treatment shows significant promise in reducing tumors
GSK’s acquisition of Nuvalent marks a significant move in the pharma industry
New treatment shows significant promise in reducing tumors
